Brokerages Set Liquidia Co. (NASDAQ:LQDA) PT at $24.00

Liquidia Co. (NASDAQ:LQDA) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $24.00.

A number of research analysts have recently weighed in on the company. Lifesci Capital started coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $10.59 on Tuesday. The company has a 50 day moving average of $10.91 and a 200-day moving average of $11.20. Liquidia has a one year low of $7.76 and a one year high of $16.99. The stock has a market cap of $896.31 million, a price-to-earnings ratio of -6.50 and a beta of 0.22.

Insider Transactions at Liquidia

In related news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the transaction, the general counsel now owns 486,048 shares in the company, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 2,526 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the transaction, the insider now directly owns 204,857 shares in the company, valued at approximately $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,007 shares of company stock worth $245,780. 30.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Whitefort Capital Management LP increased its holdings in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after purchasing an additional 927,546 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after purchasing an additional 230,820 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after purchasing an additional 32,076 shares in the last quarter. HighVista Strategies LLC increased its position in shares of Liquidia by 48.6% during the third quarter. HighVista Strategies LLC now owns 180,947 shares of the company’s stock worth $1,809,000 after acquiring an additional 59,193 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Liquidia by 12.5% during the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock worth $1,799,000 after purchasing an additional 19,932 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).